Standard Biotools Inc.

Standard Biotools Inc., doing business as Fluidigm, a for-profit manufacturer of advanced scientific instruments and reagents headquartered in South San Francisco, California, operates exclusively as a prime contractor (100% of recent awards) supplying mass cytometry systems, PCR instruments, imaging platforms, biomark readers, and associated consumables and maintenance services to 52 distinct federal agencies. The vendor does not compete under any SBA set-aside categories; recent awards split between full-and-open and small-business set-aside designations, though the latter account for a small share of dollar volume. Standard Biotools' parent-company structure includes Somalogic Operating Co., Inc., a subsidiary within the broader enterprise.

Customer concentration is highly asymmetric by dollars but dispersed by award count. The top five agencies by potential value account for 74% of combined award value, dominated by the National Heart Lung and Blood Institute at $34.4 million across 27 awards—a single customer anchoring more than 60% of the dollar footprint. The Centers for Disease Control and Prevention Pittsburgh, the National Institute of Environmental Health Sciences, the National Institute on Drug Abuse, and NOAA round out the top five, each carrying low single-digit millions. By award count, concentration is flatter: NOAA leads at 51 awards ($1.5 million), followed by USDA Agricultural Research Service Field Research Implementation and Information Delivery at 37 awards ($879 thousand), with Fish and Wildlife Service Region 1, National Cancer Institute, and related agencies contributing 28 to 29 awards each in the $300 thousand to $1.1 million range. The divergence signals that Standard Biotools' dollar exposure is anchored by a small number of high-value maintenance and equipment-upgrade contracts with specific NIH institutes, while its award frequency is distributed across smaller procurements from environmental, agricultural, and wildlife agencies.

Award volume has contracted since 2022. The vendor recorded 15 awards in 2022, declining to 4 in 2023, recovering slightly to 7 in 2024 and 8 in 2025, with 1 award recorded in early 2026. Nine awards with combined potential value of $2.2 million reach ultimate completion within the next twenty-four months, representing moderate recompete exposure concentrated in maintenance agreements and consumable supply contracts. Recent representative work includes a $639.8 million service-and-support plan awarded by the National Institute on Drug Abuse for microfluidic and imaging instruments (performance through August 2025), a $557.3 million National Institute for Minority Health and Health Disparities contract for scientific instruments and reagents (extended through September 2026), a $549.8 million Department of Veterans Affairs maintenance agreement for Hyperion Tissue Imager and Helios CyTOF systems at the Philadelphia VA Medical Center (through September 2028), and a $491.9 million VA contract for preventative maintenance and inspection of HELIOS/HYPERION CYTOF instruments (through August 2026). Smaller procurements span laboratory testing, reagent supply, and equipment repair across the National Cancer Institute, EPA, NOAA, USDA, and DOI.

Service Contract Inventory data captures minimal federal services activity above the $150,000 reporting threshold: $255 thousand in SCI-reportable invoiced revenue across FY2023 with zero contractor FTEs recorded. This reflects Standard Biotools' business model as a goods manufacturer and original equipment manufacturer providing equipment, consumables, and bundled maintenance—work that falls primarily under product procurement and equipment-support PSC codes rather than labor-intensive service contracts. On the small set of SCI records present, government-paid rates run median $11.4 thousand per hour with senior labor through $17.1 thousand per hour, consistent with specialized technical support for high-value scientific instruments. Standard Biotools engages no named subcontractors across its federal prime work.

The vendor's capability portfolio centers on mass cytometry (CyTOF and Hyperion systems), microfluidic analysis (BioMark and Juno systems), PCR instrumentation, laser capture microdissection, and single-cell genomics platforms, alongside reagent kits, antibodies, and multi-year preventative maintenance and service plans. Work is performed at federal customer sites (CDC Pittsburgh, VA medical centers, NIH campuses, USDA research stations, DOI field facilities) and at Standard Biotools' South San Francisco headquarters for equipment delivery, installation, training, and repair. The vendor's footprint across 52 agencies—spanning HHS research institutes, CDC, VA, USDA, EPA, DOI, NOAA, and others—reflects its established role as a sole-source original equipment manufacturer supplying specialized biomedical research infrastructure to the federal scientific enterprise.